Drug Conjuagate Advances for Poor-Prognosis NSCLC

(MedPage Today) -- Good results in small study of trastuzumab linked to antimicrotubule agent
Source: MedPage Today Pulmonary - Category: Respiratory Medicine Source Type: news

Related Links:

The objective-response rate was 9 percent, which included one patient with a complete response and disappearance of all tumor burden, and four patients with a partial response. Of the 48 patients whose data were assessed for change in tumor size, 24 experienced a reduction of some level. Most encouraging were the patients with a higher-level of PD-L1. They had a median overall survival of 20.2 months and a 12-month overall survival of 72.5 percent. PD-L1 presence alone, though, is not considered the only factor in how well the drug would work. Other factors such as genetic mutations of the tumor and mesothelioma cell type ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Condition:   Advanced Squamous Non-small Cell Lung Cancer Intervention:   Drug: SCT200 Sponsor:   Sinocelltech Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   TNBC - Triple-Negative Breast Cancer;   Triple Negative Breast Cancer;   Nsclc;   NSCLC Stage IV;   Non Small Cell Lung Cancer;   Non Small Cell Lung Cancer Metastatic Interventions:   Radiation: Sterotactic Body Radiotherapy/SBRT;   Drug: Standard of care Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   KRAS Gene Mutation Intervention:   Drug: TVB-2640 Sponsor:   University of Texas Southwestern Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Non-small Cell Lung Cancer Intervention:   Drug: CA and Nivolumab Sponsor:   National Cancer Center, Korea Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Cancers, Vol. 11, Pages 107: FOSB–PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer Cancers doi: 10.3390/cancers11010107 Authors: Chen-Hung Ting Kang-Yun Lee Sheng-Ming Wu Po-Hao Feng Yao-Fei Chan Yi-Chun Chen Jyh-Yih Chen Non-small cell lung cancer (NSCLC) is among the leading causes of human mortality. One reason for high rates of NSCLC mortality is that drug resistance is a major problem for both conventional chemotherapies and less-toxic targeted therapies. Thus, novel mechanistic insights into disease pathogenesis may benefit the development of urgently needed therap...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Inderpaul Singh Sehgal, Ritesh Agarwal, Sahajal Dhooria, Kuruswamy Thurai Prasad, Ashutosh N AggarwalJournal of Cytology 2019 36(1):61-64 The treatment of non-small cell lung cancer (NSCLC) includes surgical resection with curative intent in early-stage disease and chemoradiation in the advanced stage disease. Therefore, an accurate preoperative mediastinal lymph node staging is required not only to offer the appropriate treatment but also to avoid unnecessary invasive procedures including thoracotomy. The mediastinal lymph nodes can be sampled using several techniques including mediastinoscopy, surgery (open or video-ass...
Source: Journal of Cytology - Category: Cytology Authors: Source Type: research
Conditions:   NSCLC, Stage IV;   NSCLC Stage IIIB;   NSCLC, Stage IIIC;   NSCLC, Recurrent;   EGFR Exon 20 Insertion Mutation;   HER2-activating Mutation Intervention:   Drug: tarloxotinib bromide Sponsor:   Rain Therapeutics Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Contributors : S Thomson ; J HaleySeries Type : Expression profiling by arrayOrganism : Homo sapiensEpithelial – mesenchymal transition (EMT) is an important contributor to the invasion and metastasis of epithelial-derived cancers. While considerable effort has focused in the regulators involved in the transition process, we have focused on consequences of EMT to prosurvival signaling. Changes in distinct metastable and ‘epigentically-fixed’ EMT states were measured by correlation of protein, phosphoprotein, phosphopeptide and RNA transcript abundance. The assembly of 1167 modulated components into functi...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
More News: Herceptin | Non-Small Cell Lung Cancer | Respiratory Medicine | Study